Services
Company
Legal and Governance
Insights / Articles
What DDW 2026 Revealed About the Future of IBD
Written by Dana Franznick, AVP, Medical Strategy on Wednesday, June 17, 2026
If DDW 2025 was about whether the next wave of IBD therapies would work, DDW 2026 was about something more demanding: what “working” will ultimately need to mean. The bar is rising, the pipeline is more crowded, and success is being redefined from efficacy alone to a mix of durability, sequencing, and treatment burden in real-world practice. DDW 2026 brought that shift into much sharper focus across IBD.
Nowhere is that shift more visible than in TL1A inhibition, which has emerged as one of the most closely watched new mechanisms in IBD. Tulisokibart, duvakitug, and afimkibart continue to represent the leading edge of this class, and the field is applying increasing rigor to how early signals translate into later-stage success.
In ulcerative colitis, studies such as ARTEMIS-UC highlighted the use of composite endpoints like disease clearance, integrating symptomatic remission, endoscopic improvement, and histologic healing. This shifts the narrative toward deeper and more durable control. Of increasing interest is the TL1A fibrosis story. In preclinical and in vivo models, TL1A signaling directly promotes intestinal fibrogenesis and tissue remodeling, raising the hypothesis that we might eventually influence the longer-term risk of scarring, strictures, and surgery. For now, however, fibrosis remains a compelling but clinically unproven dimension of potential class differentiation that should be watched with appropriate caution.
Beyond TL1A, the pipeline is increasingly shaped by three strategic themes:
- Combination approaches: JNJ-4804 combines IL 23 and TNF blockade, and DDW 2026 reinforced both the promise and the complexity of this strategy. Phase 2 data were mixed at the primary endpoint level, yet the signal in more refractory patients appears strong enough to justify Phase 3 development, suggesting that combination biologics may find their role in later-line, high-need segments rather than as a universal first-line solution.
- Longer half-life biologics: Agents such as SPY001 (anti-α4β7) and SPY003 (IL-23 p19) aim to reduce dosing frequency, positioning convenience and adherence as key elements of value. Over time, these attributes are likely to pressure labels and guidelines to be more explicit about where less frequent dosing can be used to support persistence and to differentiate in relatively crowded mechanism classes.
- Oral therapies: Icotrokinra, obefazimod, PDE4-directed agents, and NIM-1324 introduce mechanistic diversity with the potential to simplify treatment sequencing and reduce patient burden. As these programs mature, oral options will become increasingly relevant for step therapy design, earlier-line positioning, and shared decision-making, with patient preference playing a more visible role in access and adoption discussions.
Taken together, these developments point toward a more complex but also more configurable IBD landscape over the next three to five years. The strategic question for sponsors will be less about whether an individual asset can achieve remission in a trial, and more about how clearly it can claim a defined role within an evolving treatment sequence, by line of therapy, mechanism mix, and patient profile.
Biomarkers were a quieter but important theme. Predictive approaches, such as DR3 pathway enrichment strategies associated with TL1A programs, highlight the potential to identify responders upfront. At the same time, established and emerging tools, including tissue markers (IL-22, IL-17), serum CRP, fecal calprotectin, and intestinal ultrasound, continue to evolve in their ability to guide treatment selection, assess depth of response, and monitor recurrence.
These same questions of durability, positioning, and clinical role are also shaping more established therapies. DDW 2026 highlighted the continued evolution of risankizumab, while renewed focus on infliximab switching, precision-guided dosing, and drug clearance underscored that innovation is not limited to new mechanisms, but also to using existing therapies more effectively.
At OPEN Health, this is where we help clients create strategic advantage. As endpoints evolve beyond binary remission, as mechanisms like TL1A converge within crowded classes, and as combinations, long-acting biologics, and oral agents change how therapies are sequenced and reimbursed, the real work is turning complex data into a clear role in practice. We partner with clients to define that role, sharpen differentiation around the endpoints and patient segments that matter, and translate fast-moving science into strategies that resonate with clinicians, payers, and patients.
IBD strategy is more consequential than it was two years ago. The teams that move fastest from evidence to a clear, credible role in practice will have the advantage.
If that is the challenge your program is facing, reach out.